News

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...
Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...
The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...
Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...
Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.
Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...
The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.
Novavax Inc. shares fell after the Wall Street Journal reported that US regulators asked the company to conduct another ...
Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...
The FDA was on track to grant Novavax full approval by its April 1 target date, according to two people with direct knowledge of the situation who spoke on condition of anonymity to discuss ...